Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Receives Final FDA Approval for Generic Zegerid
Tweet Send to a Friend
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (NYSE: PRX), PT $32.
Needham analyst says, "PRX has received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "PRX has received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
